The Role of Hepatoprotection in the Treatment of Pulmonary Tuberculosis Comorbid with HIV Infection and Chronic Viral Hepatitis

The increase in the proportion of comorbid forms of socially significant infections, in particular the combination of tuberculosis with HIV infection and chronic viral hepatitis, is a pressing problem, including of a therapeutic nature: on the one hand, the combined use of anti-tuberculosis and antiretroviral therapy creates an additional burden on the liver; on the other hand, the situation is aggravated by specific disorders of its function associated with the presence of a chronic viral infection, most often hepatitis C and B. In this regard, the inclusion of drugs with hepatoprotective properties in the treatment regimens for this pathology is advisable. The article presents a clinical observation of the effectiveness of remaxol inclusion in the treatment regimen of a patient with disseminated pulmonary tuberculosis, comorbid with HIV infection and chronic hepatitis C with signs of a hepatotoxic reaction to the etiotropic therapy (the main course of treatment). The drug was administered according to the scheme: 400.0 ml intravenously by drip every other day No. 5, then 400.0 intravenously by drip once a week No. 4. The treatment with remaxol contributed to the relief of clinical and laboratory signs of drug-induced liver damage, which in turn made it possible not to interrupt the course of etiotropic therapy, while the improvement of the general condition of the patient increased his adherence to the treatment. The obtained results allow us to continue research in this direction.

1. Tuberculosis in adults: clinical guidelines. Russian Society of Phthisiologists. Moscow: 2021; 135. (in Russian)

2. Federal clinical guidelines for the prevention, diagnosis and treatment of tuberculosis in patients with HIV infection. Russian Society of Phthisiologists. Moscow: 2016; 42.

3. Global tuberculosis report 2024. Geneva: World Health Organization; 2024. Licence: CC BY-NC-SA 3.0 IGO

4. Dolgushina A. I., Volchegorskij I. A., Novoselov P. N., Ushkareva Eh. V., Olevskaya E. R., Kuznetsova A. S. Hepatotoxicity of anti-tuberculosis drugs. Ehksperimental'naya i Klinicheskaya Gastroehnterologiya. 2018; 156 (8): 116–124. https://doi.org/10.31146/1682-8658-ecg-156-8-116-124. (in Russian)

5. Björnsson H. K., Björnsson E. S. Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management. Eur J Intern Med. 2022 Mar; 97: 26–31. doi: 10.1016/j.ejim.2021.10.035. Epub 2021 Nov 9.

6. Drug-induced liver injury (clinical guidelines for physicians)/ pod. red. V. T. Ivashkina Rossijskij Zhurnal Gastroehnterologii, Gepatologii, Koloproktologii. 2019; 29 (1): 101–131. doi: https://doi.org/10.22416/1382-4376-2019-29-1-101-131>. (in Russian)

7. Krylova I. N., TSublova E. G. Mechanisms of hepatotoxic action of drugs Ehksperimental'naya i Klinicheskaya Farmakologiya. 2020, 83 (10): 28–32. doi: https://doi.org/10.30906/0869-2092-2020-83-10-26-32.

8. Sukhanov D. S., Timofeev E. V., Alekseeva Yu. S., Azovtsev D. Yu. Drug-induced liver damage in tuberculosis. Development mechanisms and diagnostic methods Juvenis Scientia. 2023; 9 (1): 24–42. doi: https://doi.org/10.32415/jscientia_2023_9_1_24-42. (in Russian)

9. Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection. Ehpidemiologiya i Infektsionnye Bolezni. 2018; 4 (Prilozhenie, chast I): 1–84. (in Russian)

10. Isentaev A. A., Bakieva A. R. Hepatotoxic effect of anti-tuberculosis drugs. Byulleten' Meditsinskikh. Internet-Konferentsij (ISSN 2224-6150). 2022; 12 (4): 100–102. ID: 2022–04-1749-A-19654. (in Russian)

11. Maev I. V., Polunina T. E. Drug-induced liver injury: a diagnosis of exclusion. Terapevticheskij Arkhiv. 2023; 95 (8): 611–620. doi: https://doi.org/10.26442/00403660.2023.08.202329. (in Russian)

12. Mazina N. K., Mazin P. V. Meta-analytical approach to assessing the clinical efficacy of the infusion succinate-containing drug Remaxol in liver pathology of various genesis. Antibiot Khimioter = Antibiotics and Chemotherapy. 2015; 60 (11–12): 43–49.(in Russian).